Bergen, Norway - 15 March 2021: BerGenBio ASA (OSE:BGBIO) will be holding its
Annual General Meeting (virtually) on 19 March 2021 at 15:00 hours (CET).

The chairman of the board of directors of BerGenBio ASA ("BergenBio"), Sveinung
Hole, has received proxies to vote at BerGenBio's Annual General Meeting to be
held on 19 March 2021 for a total of 7,570,836 shares, representing approx.
8.62% of the total share capital in BerGenBio ASA.

The proxies received are valid only for the Annual General Meeting to be held on
19 March 2021 and will automatically lapse thereafter.

- END -

About?BerGenBio?ASA

BerGenBio?is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate,?bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer, leukaemia
and COVID-19. A first-in-class functional blocking anti-AXL
antibody,?tilvestamab, is undergoing?phase I clinical testing. In
parallel,?BerGenBio?is developing?a?companion diagnostic test to identify
patient populations most likely to benefit from ?AXL inhibition: this is
expected to facilitate more efficient registration trials supporting a precision
medicine-based commercialisation strategy.

BerGenBio?is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

ir@bergenbio.com

Richard Godfrey, CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86?513

This information is subject to disclosure pursuant to section 4-2 of the
Norwegian Securities Trading Act.